431898-65-6 | Ps-1145

Packsize	Purity	Availability	Price	Discounted Price
1mg	98%	in stock	$42.00	$29.00
5mg	98%	in stock	$85.00	$59.00
10mg	98%	in stock	$128.00	$89.00
25mg	98%	in stock	$192.00	$134.00
50mg	98%	in stock	$288.00	$201.00
100mg	98%	in stock	$489.00	$342.00

Description

• Catalog Number: AD25493
• Chemical Name: Ps-1145
• CAS Number: 431898-65-6
• Molecular Formula: C17H11ClN4O
• Molecular Weight: 322.7484
• MDL Number: MFCD18089825
• SMILES: Clc1cc(NC(=O)c2cccnc2)c2c(c1)c1ccncc1[nH]2

Computed Properties

• Complexity: 448
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 23
• Hydrogen Bond Acceptor Count: 3
• Hydrogen Bond Donor Count: 2
• Rotatable Bond Count: 2
• XLogP3: 2.7

Literature

• Bisphenol A induces Pomc gene expression through neuroinflammatory and PPARγ nuclear receptor-mediated mechanisms in POMC-expressing hypothalamic neuronal models.

  Molecular and cellular endocrinology 20180824

• Central Leptin and Tumor Necrosis Factor-α (TNFα) in Diurnal Control of Blood Pressure and Hypertension.

  The Journal of biological chemistry 20160715

• 18β-Glycyrrhetinic acid suppresses TNF-α induced matrix metalloproteinase-9 and vascular endothelial growth factor by suppressing the Akt-dependent NF-κB pathway.

  Toxicology in vitro : an international journal published in association with BIBRA 20140801

• Identification of potent Yes1 kinase inhibitors using a library screening approach.

  Bioorganic & medicinal chemistry letters 20130801

• Clarithromycin inhibits interleukin-13-induced goblet cell hyperplasia in human airway cells.

  American journal of respiratory cell and molecular biology 20111101

• Lipopolysaccharide stimulates adrenal steroidogenesis in rodent cells by a NFκB-dependent mechanism involving COX-2 activation.

  Molecular and cellular endocrinology 20110430

• In CD28-costimulated human naïve CD4+ T cells, I-κB kinase controls the expression of cell cycle regulatory proteins via interleukin-2-independent mechanisms.

  Immunology 20101001

• Central administration of interleukin-4 exacerbates hypothalamic inflammation and weight gain during high-fat feeding.

  American journal of physiology. Endocrinology and metabolism 20100701

• Inhibition of IKK-beta: a new development in the mechanism of the anti-obesity effects of PTP1B inhibitors SA18 and SA32.

  Bioorganic & medicinal chemistry letters 20100201

• Taurine prevents arsenic-induced cardiac oxidative stress and apoptotic damage: role of NF-kappa B, p38 and JNK MAPK pathway.

  Toxicology and applied pharmacology 20091001

• Nitric oxide inhibits IFN regulatory factor 1 and nuclear factor-kappaB pathways in rhinovirus-infected epithelial cells.

  The Journal of allergy and clinical immunology 20090901

• IL-10 attenuates TNF-alpha-induced NF kappaB pathway activation and cardiomyocyte apoptosis.

  Cardiovascular research 20090401

• Potent inhibition of thyroid cancer cells by the MEK inhibitor PD0325901 and its potentiation by suppression of the PI3K and NF-kappaB pathways.

  Thyroid : official journal of the American Thyroid Association 20080801

• The selectivity of protein kinase inhibitors: a further update.

  The Biochemical journal 20071215

• Bortezomib inhibits human osteoclastogenesis.

  Leukemia 20070901

• Repression of inflammatory gene expression in human pulmonary epithelial cells by small-molecule IkappaB kinase inhibitors.

  The Journal of pharmacology and experimental therapeutics 20070501

• Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060915

• Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells.

  Molecular cancer therapeutics 20060901

• Validation of the anti-inflammatory properties of small-molecule IkappaB Kinase (IKK)-2 inhibitors by comparison with adenoviral-mediated delivery of dominant-negative IKK1 and IKK2 in human airways smooth muscle.

  Molecular pharmacology 20060801

• NF-kappaB as a target for the prevention of graft-versus-host disease: comparative efficacy of bortezomib and PS-1145.

  Blood 20060115

• The NF-kappaB pathway blockade by the IKK inhibitor PS1145 can overcome imatinib resistance.

  Leukemia 20060101

• Tpl2 (tumor progression locus 2) phosphorylation at Thr290 is induced by lipopolysaccharide via an Ikappa-B Kinase-beta-dependent pathway and is required for Tpl2 activation by external signals.

  The Journal of biological chemistry 20050527

• Human myeloma cells adhere to fibronectin in response to hepatocyte growth factor.

  Haematologica 20050401

• Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050101

• Anti-inflammatory inhibitors of IkappaB kinase in asthma and COPD.

  Current opinion in investigational drugs (London, England : 2000) 20041101

• Novel IKK inhibitors: beta-carbolines.

  Bioorganic & medicinal chemistry letters 20030721

• Moving disease biology from the lab to the clinic.

  Cancer 20030201

• Novel therapies for multiple myeloma.

  British journal of haematology 20030101

• NF-kappa B as a therapeutic target in multiple myeloma.

  The Journal of biological chemistry 20020510